Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 2105610, 17 pages
https://doi.org/10.1155/2017/2105610
Research Article

Sulfonanilide Derivatives in Identifying Novel Aromatase Inhibitors by Applying Docking, Virtual Screening, and MD Simulations Studies

1Division of Applied Life Science (BK21 Plus), Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Systems and Synthetic Agrobiotech Center (SSAC), Research Institute of Natural Science (RINS), Gyeongsang National University (GNU), 501 Jinju-daero, Jinju 52828, Republic of Korea
2Division of Quality of Life, Korea Research Institute of Standards and Science, Daejeon 34113, Republic of Korea
3Bio-Computing Major, Korean German Institute of Technology, Seoul 07582, Republic of Korea

Correspondence should be addressed to Keun Woo Lee; rk.ca.ung@eelwk

Received 11 May 2017; Revised 31 July 2017; Accepted 27 August 2017; Published 17 October 2017

Academic Editor: Mai S. Li

Copyright © 2017 Shailima Rampogu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Su, R. Tian, M. V. Darby, and R. W. Brueggemeier, “Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: Synthesis, biological evaluation, and ligand-based pharmacophore identification,” Journal of Medicinal Chemistry, vol. 51, no. 5, pp. 1126–1135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. S. D. V. Rampogu, “Role of breast cancer inhibitors on diabetes mellitus- an in silico approach,” Journal of Diabetes and Metabolic Disorders, vol. 14, no. 1, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Dixon, “Endocrine Resistance in Breast Cancer,” New Journal of Science, vol. 2014, no. 10, pp. 1–27, 2014. View at Publisher · View at Google Scholar
  4. T. W. Miller, J. M. Balko, E. M. Fox et al., “ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer,” Cancer Discovery, vol. 1, no. 4, pp. 338–351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Viedma-RodríGuez, L. Baiza-Gutman, F. Salamanca-Gómez et al., “Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review),” Oncology Reports, vol. 32, no. 1, pp. 3–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Marino, P. Galluzzo, and P. Ascenzi, “Estrogen signaling multiple pathways to impact gene transcription,” Current Genomics, vol. 7, no. 8, pp. 497–508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Y. Maximov, T. M. Lee, and V. Craig Jordan, “The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice,” Current Clinical Pharmacology, vol. 8, no. 2, pp. 135–155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. L. A. Martin, I. Farmer, S. R. D. Johnston, S. Ali, C. Marshall, and M. Dowsett, “Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation,” The Journal of Biological Chemistry, vol. 278, no. 33, pp. 30458–30468, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. S. R. D. Johnston, J. Head, S. Pancholi et al., “Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer,” Clinical Cancer Research, vol. 9, no. 1 Pt 2, pp. 524S–532S, 2003. View at Google Scholar
  10. C. J. Fabian, “The what, why and how of aromatase inhibitors: Hormonal agents for treatment and prevention of breast cancer,” International Journal of Clinical Practice, vol. 61, no. 12, pp. 2051–2063, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Hong, A. Didwania, O. Olopade, and P. Ganschow, “The expanding use of third-generation aromatase inhibitors: What the general internist needs to know,” Journal of General Internal Medicine, vol. 24, no. 2, pp. S383–S388, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Geisler, “Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole- of clinical importance?” British Journal of Cancer, vol. 104, no. 7, pp. 1059–1066, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. W. R. Miller, J. Bartlett, A. M. H. Brodie et al., “Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?” Oncologist, vol. 13, no. 8, pp. 829–837, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Ahmad and Shagufta, “Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer,” European Journal of Medicinal Chemistry, vol. 102, pp. 375–386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. E. di Salle, G. Ornati, D. Giudici, M. Lassus, T. R. J. Evans, and R. C. Coombes, “Exemestane (FCE 24304), A new steroidal aromatase inhibitor,” Journal of Steroid Biochemistry and Molecular Biology, vol. 43, no. 1-3, pp. 137–143, 1992. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Hong, B. Yu, M. Sherman, Y.-C. Yuan, D. Zhou, and S. Chen, “Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase,” Molecular Endocrinology, vol. 21, no. 2, pp. 401–414, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Vosooghi, L. Firoozpour, A. Rodaki et al., “Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs,” DARU, Journal of Pharmaceutical Sciences, vol. 22, 83 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Pingaew, V. Prachayasittikul, P. Mandi et al., “Synthesis and molecular docking of 1,2,3-triazole-based sulfonamides as aromatase inhibitors,” Bioorganic and Medicinal Chemistry, vol. 23, no. 13, Article ID 12248, pp. 3472–3480, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Rampogu and M. Rampogu Lemuel, “Network Based Approach in the Establishment of the Relationship between Type 2 Diabetes Mellitus and Its Complications at the Molecular Level Coupled with Molecular Docking Mechanism,” BioMed Research International, vol. 2016, Article ID 6068437, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Ghosh, J. Griswold, M. Erman, and W. Pangborn, “Structural basis for androgen specificity and oestrogen synthesis in human aromatase,” Nature, vol. 457, no. 7226, pp. 219–223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Fei, L. Zhou, T. Liu, and X.-Y. Tang, “Pharmacophore modeling, virtual screening, and molecular docking studies for discovery of novel Akt2 inhibitors,” International Journal of Medical Sciences, vol. 10, no. 3, pp. 265–275, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. M. K. Abdel-Hamid and A. McCluskey, “In Silico docking, molecular dynamics and binding energy insights into the bolinaquinone-clathrin terminal domain binding site,” Molecules, vol. 19, no. 5, pp. 6609–6622, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Fatima, A. B. H. Abdul, R. Abdullah, R. A. Karjiban, and V. S. Lee, “Binding mode analysis of zerumbone to key signal proteins in the tumor necrosis factor pathway,” International Journal of Molecular Sciences, vol. 16, no. 2, pp. 2747–2766, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Sharma, M. Ashaduzzaman, M. Golabi, A. Shriwastav, K. Bisetty, and A. Tiwari, “Studies on Bacterial Proteins Corona Interaction with Saponin Imprinted ZnO Nanohoneycombs and Their Toxic Responses,” ACS Applied Materials and Interfaces, vol. 7, no. 43, pp. 23848–23856, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. D. van der Spoel, E. Lindahl, B. Hess, G. Groenhof, A. E. Mark, and H. J. C. Berendsen, “GROMACS: fast, flexible, and free,” Journal of Computational Chemistry, vol. 26, no. 16, pp. 1701–1718, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. H. J. C. Berendsen, D. van der Spoel, and R. van Drunen, “GROMACS: a message-passing parallel molecular dynamics implementation,” Computer Physics Communications, vol. 91, no. 1–3, pp. 43–56, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Lindahl, B. Hess, and D. van der Spoel, “GROMACS 3.0: a package for molecular simulation and trajectory analysis,” Journal of Molecular Modeling, vol. 7, no. 8, pp. 306–317, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Zoete, M. A. Cuendet, A. Grosdidier, and O. Michielin, “SwissParam: a fast force field generation tool for small organic molecules,” Journal of Computational Chemistry, vol. 32, no. 11, pp. 2359–2368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Parrinello and A. Rahman, “Polymorphic transitions in single crystals: a new molecular dynamics method,” Journal of Applied Physics, vol. 52, no. 12, 7182 pages, 1981. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Miyamoto and P. A. Kollman, “Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models,” Journal of Computational Chemistry, vol. 13, no. 8, pp. 952–962, 1992. View at Publisher · View at Google Scholar
  31. B. Hess, H. Bekker, H. J. C. Berendsen, and J. G. E. M. Fraaije, “LINCS: a linear Constraint Solver for molecular simulations,” Journal of Computational Chemistry, vol. 18, no. 12, pp. 1463–1472, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Darden, D. York, and L. Pedersen, “Particle mesh Ewald: an N·log(N) method for Ewald sums in large systems,” The Journal of Chemical Physics, vol. 98, no. 12, 10089 pages, 1993. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Humphrey, A. Dalke, and K. Schulten, “VMD: visual molecular dynamics,” Journal of Molecular Graphics, vol. 14, no. 1, pp. 33–38, 1996. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Kumari, R. Kumar, and A. Lynn, “g_mmpbsa—A GROMACS tool for high-throughput MM-PBSA calculations,” Journal of Chemical Information and Modeling, vol. 54, no. 7, pp. 1951–1962, 2014. View at Publisher · View at Google Scholar
  35. N. A. Baker, D. Sept, S. Joseph, M. J. Holst, and J. A. McCammon, “Electrostatics of nanosystems: application to microtubules and the ribosome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 18, pp. 10037–10041, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Homeyer and H. Gohlke, “Free energy calculations by the Molecular Mechanics Poisson-Boltzmann Surface Area method,” Molecular Informatics, vol. 31, no. 2, pp. 114–122, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. P. A. Kollman, I. Massova, C. Reyes et al., “Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models,” Accounts of Chemical Research, vol. 33, no. 12, pp. 889–897, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Piñero, Á. Bravo, N. Queralt-Rosinach et al., “DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants,” Nucleic Acids Research, vol. 45, no. D1, pp. D833–D839, 2017. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Piñero, N. Queralt-Rosinach, À. Bravo et al., “DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes,” Database, vol. 2015, Article ID bav028, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Wu, R. Jiang, M. Q. Zhang, and S. Li, “Network-based global inference of human disease genes,” Molecular Systems Biology, vol. 4, no. 1, 189 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Shlomi, M. N. Cabili, M. J. Herrgård, B. Ø. Palsson, and E. Ruppin, “Network-based prediction of human tissue-specific metabolism,” Nature Biotechnology, vol. 26, no. 9, pp. 1003–1010, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Wang, N. Gulbahce, and H. Yu, “Network-based methods for human disease gene prediction,” Briefings in Functional Genomics, vol. 10, no. 5, pp. 280–293, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Chen, H. Zhang, Z. Zhang, Y. Cao, and W. Tang, “Network-based inference methods for drug repositioning,” Computational and Mathematical Methods in Medicine, vol. 2015, Article ID 130620, 7 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. J. A. DiMasi, N. R. Bryant, and L. Lasagna, “New drug development in the United States from 1963 to 1990,” Clinical Pharmacology & Therapeutics, vol. 50, no. 5-1, 1991. View at Google Scholar
  45. C. P. Adams and V. Van Brantner, “Estimating the cost of new drug development: Is it really $802 million dollars?” Health Affairs, vol. 25, no. 2, pp. 420–428, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Ntie-Kang, C. V. Simoben, B. Karaman et al., “Pharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plants,” Drug Design, Development and Therapy, vol. 10, pp. 2137–2154, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. S.-H. Lu, J. W. Wu, H.-L. Liu et al., “The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies,” Journal of Biomedical Science, vol. 18, no. 1, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Pajouhesh and G. R. Lenz, “Medicinal chemical properties of successful central nervous system drugs,” NeuroRx, vol. 2, no. 4, pp. 541–553, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Y. Lobanov, N. S. Bogatyreva, and O. V. Galzitskaya, “Radius of gyration as an indicator of protein structure compactness,” Molecular Biology, vol. 42, no. 4, pp. 623–628, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. K. H. Liao, K.-B. Chen, W.-Y. Lee, M.-F. Sun, C.-C. Lee, and C. Y.-C. Chen, “Ligand-Based and Structure-Based Investigation for Alzheimer’s Disease from Traditional Chinese Medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 364819, pp. 1–16, 2014. View at Publisher · View at Google Scholar
  51. R. Bavi, R. Kumar, S. Rampogu et al., “Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation,” Journal of Receptors and Signal Transduction, vol. 37, no. 3, pp. 224–238, 2017. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Bavi, R. Kumar, S. Rampogu et al., “Molecular interactions of UvrB protein and DNA from Helicobacter pylori: Insight into a molecular modeling approach,” Computers in Biology and Medicine, vol. 75, pp. 181–189, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. P.-C. Chen and S. Kuyucak, “Accurate determination of the binding free energy for KcsA-charybdotoxin complex from the potential of mean force calculations with restraints,” Biophysical Journal, vol. 100, no. 10, pp. 2466–2474, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Rajamanikandan, J. Jeyakanthan, and P. Srinivasan, “Molecular Docking, Molecular Dynamics Simulations, Computational Screening to Design Quorum Sensing Inhibitors Targeting LuxP of Vibrio harveyi and Its Biological Evaluation,” Applied Biochemistry and Biotechnology, vol. 181, no. 1, pp. 192–218, 2017. View at Publisher · View at Google Scholar · View at Scopus
  55. D. W. Wright, B. A. Hall, O. A. Kenway, S. Jha, and P. V. Coveney, “Computing clinically relevant binding free energies of HIV-1 protease inhibitors,” Journal of Chemical Theory and Computation, vol. 10, no. 3, pp. 1228–1241, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. M. B. Yilmaz, A. Pazarbasi, A. I. Guzel et al., “Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey,” Genetics and Molecular Research, vol. 10, no. 3, pp. 1999–2008, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. J.-J. Lu, W. Pan, Y.-J. Hu, and Y.-T. Wang, “Multi-target drugs: The trend of drug research and development,” PLoS ONE, vol. 7, no. 6, Article ID e40262, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. J. P. Overington, B. Al-Lazikani, and A. L. Hopkins, “How many drug targets are there?” Nature Reviews Drug Discovery, vol. 5, no. 12, pp. 993–996, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Lee, S. Kang, and W. Kim, “Drug repositioning for cancer therapy based on large-scale drug-induced transcriptional signatures,” PLoS ONE, vol. 11, no. 3, Article ID e0150460, 2016. View at Publisher · View at Google Scholar
  60. T.-W. Kim, “Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer’s Disease,” Neurotherapeutics, vol. 12, no. 1, pp. 132–142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. E. L. Leung, Z. W. Cao, Z. H. Jiang, H. Zhou, and L. Liu, “Network-based drug discovery by integrating systems biology and computational technologies,” Briefings in Bioinformatics, vol. 14, no. 4, pp. 491–505, 2013. View at Publisher · View at Google Scholar